Home Parkinson's Minerva Neuroscience shares jump on Parkinson’s drug trial results

Minerva Neuroscience shares jump on Parkinson’s drug trial results

1023
0
Caregiver giving medication to her senior patient

Minerva Neurosciences Inc shares jumped after a biotech clinical trial of a drug similar to its new drug, MIN-301, improved Parkinson’s disease symptoms in non-human Primates.

Minerva plans human clinical trials shortly.

Dr. Rémy Luthringer, Ph.D., president and CEO of Minerva said, “We believe MIN-301 and other peptides from our neuregulin platform may represent the next generation of therapies with neuroprotective activities in Parkinson’s and other neurodegenerative disorders.”

Previous articleStem cell transplants make dopamine for Parkinson’s patients
Next articleKetogenic Diet improves symptoms in Parkinson’s patients